Wednesday, January 22, 2014
Anergis SA, of Epalinges, Switzerland, was issued Japanese patent No. 5389326 for its Contiguous Overlapping Peptide (COP) technology, which is used to develop allergy vaccines.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.